Praxis Precision Says FDA Accepts Ulixacaltamide HCl NDA For Review To Treat Essential Tremor

Praxis Precision Medicines said the FDA accepted its NDA for ulixacaltamide HCl for adult essential tremor, a regulatory milestone that moves the candidate closer to potential approval. The update is positive for the pipeline but remains procedural, with no approval decision yet and limited immediate market impact.

Analysis

Praxis Precision Medicines said the FDA accepted its NDA for ulixacaltamide HCl for adult essential tremor, a regulatory milestone that moves the candidate closer to potential approval. The update is positive for the pipeline but remains procedural, with no approval decision yet and limited immediate market impact.